BCL3 establishes itself as a dual biomarker because it functions as an interface between cancer development and immune resistance mechanisms, which indicates therapeutic and prognostic value. Precise medicine approaches now pave the path for cancer treatment towards individualized strategies combining molecular testing and immune system examination to determine treatment selection. The gene discussed is BCL3; the disease is cancer.